Background: The chemotherapeutic agent doxorubicin (DOX) has been widely used in the treatment of solid tumors and hematological malignancies [1]. However, serious adverse side effects have emerged in patients treated with this drug, notably cardiotoxicity [2]. Moreover, aging is a risk factor for the development of cardiovascular diseases in cancer treated patients [3]. Objective: We herein aimed to evaluate t...